A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)

INTRODUCTION: Human epidermal growth factor receptor 2 (HER2) gene amplification and mutations have emerged as oncogenic drivers and therapeutic targets not limited to breast and gastric cancers, but also in a variety of cancers. However, even if an actionable gene alteration is found, the incidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Kenta, Ishibashi, Eri, Kubo, Toshio, Harada, Yohei, Hayashi, Hideyuki, Kano, Masayuki, Shimizu, Yasushi, Shirota, Hidekazu, Mori, Yukiko, Muto, Manabu, Ishioka, Chikashi, Dosaka-Akita, Hirotoshi, Matsubara, Hisahiro, Nishihara, Hiroshi, Sueoka-Aragane, Naoko, Toyooka, Shinichi, Hirakawa, Akihiro, Tateishi, Ukihide, Miyake, Satoshi, Ikeda, Sadakatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592999/
https://www.ncbi.nlm.nih.gov/pubmed/32769873
http://dx.doi.org/10.1097/MD.0000000000021457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592999/
https://www.ncbi.nlm.nih.gov/pubmed/32769873
http://dx.doi.org/10.1097/MD.0000000000021457

Ejemplares similares